Questcor Announces Conference Call and Webcast on June 14, 2012 to Review
Commercialization Strategy for Rheumatology Indications for Acthar
ANAHEIM, Calif., June 11, 2012 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) today announced that it will host an analyst and
investor conference call on Thursday, June 14, 2012 at 1:30 p.m. PDT / 4:30 p.m.
EDT to review the Company's commercialization strategy for H.P. Acthar? Gel
(repository corticotropin injection) for the following rheumatology-related
FDA-approved indications on the label for Acthar:
Collagen Diseases: "during an exacerbation or as maintenance therapy in selected
cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)."
Rheumatic Disorders: "as adjunctive therapy for short-term administration (to
tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis,
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may
require low-dose maintenance therapy), Ankylosing spondylitis."
Conference Call Details
To participate in the live call by telephone, please dial (877) 354-0215 for
domestic participants and (253) 237-1173 for international participants
approximately 5-10 minutes prior to the start time. A listen-only webcast of the
call including the presentation slides will be accessible in the "Investor
Relations" section under "Events & Presentations" at
ir.questcor.com. If listening via telephone, to view the
accompanying presentation slides, navigate to the live webcast as noted above and
choose the "No Audio -- Slides Only" option to view the slides in conjunction
with the live conference call. Listeners should go to the website at least 15
minutes prior to the start time to install any necessary software.
An audio replay of the call will be available for 30 days following the call.
This replay can be accessed by dialing (855) 859-2056 for domestic callers and
(404) 537-3406 for international callers, both using Conference ID #88310576. An
archived webcast will also be available at ir.questcor.com.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary
product helps patients with serious, difficult-to-treat medical conditions.
Questcor's primary product is H.P. Acthar? Gel (repository corticotropin
injection), an injectable drug that is approved by the FDA for the treatment of
19 indications. Of these 19 indications, Questcor currently generates
substantially all of its net sales from three indications: the treatment of
proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute
exacerbations of multiple sclerosis in adults, and the treatment of infantile
spasms in children under two years of age. With respect to nephrotic syndrome,
the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria
in the nephrotic syndrome without uremia of the idiopathic type or that due to
lupus erythematosus." Questcor is also currently preparing to launch a pilot
effort in rheumatology, as Acthar is approved for several rheumatology-related
conditions including Lupus, Dermatomyositis, Polymyositis and Rheumatoid
Arthritis. Questcor is also exploring the possibility of developing markets for
other on-label indications and the possibility of pursuing FDA approval of
additional indications not currently on the Acthar label where there is high
unmet medical need. For more information about Questcor, please visit
questcor.com. |
